CN107496435A - 金线莲苷在制备抗疲劳药物中的应用 - Google Patents
金线莲苷在制备抗疲劳药物中的应用 Download PDFInfo
- Publication number
- CN107496435A CN107496435A CN201710712122.7A CN201710712122A CN107496435A CN 107496435 A CN107496435 A CN 107496435A CN 201710712122 A CN201710712122 A CN 201710712122A CN 107496435 A CN107496435 A CN 107496435A
- Authority
- CN
- China
- Prior art keywords
- food
- anoectochilus
- fatigue
- anoectochilus roxburghii
- fatigue medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000934230 Anoectochilus roxburghii Species 0.000 title claims abstract description 48
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 46
- 229930182470 glycoside Natural products 0.000 title claims abstract description 44
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 241000719837 Anoectochilus Species 0.000 claims description 16
- 241000632227 Antenoron Species 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000287 crude extract Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 241000233855 Orchidaceae Species 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 239000010931 gold Substances 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 241000719836 Anoectochilus formosanus Species 0.000 claims description 4
- 241001532036 Aspidistra Species 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 240000002853 Nelumbo nucifera Species 0.000 claims description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008619 Xingren Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000033001 locomotion Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229960001866 silicon dioxide Drugs 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000009182 swimming Effects 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- MQEPWBMWFIVRPS-ZGSHZZHUSA-N (3R)-5-Oxotetrahydro-3-furanyl beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC(=O)OC1 MQEPWBMWFIVRPS-ZGSHZZHUSA-N 0.000 description 6
- MQEPWBMWFIVRPS-UHFFFAOYSA-N goodyeroside A Natural products OC1C(O)C(O)C(CO)OC1OC1CC(=O)OC1 MQEPWBMWFIVRPS-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000003304 gavage Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 206010057315 Daydreaming Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241001486992 Taiwanofungus camphoratus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- -1 lactone glycoside Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及医药技术领域,具体是金线莲苷在制备抗疲劳药物或食品中的应用。本发明提供了金线莲苷新的医药用途,经药效学研究表明,本发明的金线莲苷可显著延长负重小鼠游泳时间,抗疲劳效果显著,可用于制备抗疲劳药物或食品。本发明为寻求新的抗疲劳药物提供了一种新的来源。
Description
技术领域
本发明涉及医药技术领域,具体地说,是以开唇兰属及其近缘属植物为原料制备的金线莲苷在抗疲劳药物或食品中的应用。
背景技术
疲劳是一种生理心理现象,是机体脑力与体力活动过度,精神刺激等因素所致。一般可以分为外周疲劳、中枢疲劳两类。随着经济的发展,生活节奏的加快,长时间的工作而得不到有效睡眠或生活不规律,导致越来越多的人感到疲惫、肌肉疼痛、注意力不集中、记忆力下降、情绪低落、睡眠障碍等。这些症状,临床上一般诊断为疲劳,涵盖外周和中枢疲劳,外周疲劳多发于体力劳动者,中枢疲劳多发于脑力劳动者。疲劳尤其是中枢疲劳长期得不到有效的治疗就会转变为慢性疲劳甚至“过劳死”,严重干扰病人的日常生活和工作。目前临床上的抗疲劳药物由于副作用、成瘾性、兴奋性等不良反应,而受到严格的限制。因此,寻求高效低毒的抗疲劳药物仍是世界医学界面临的一项艰巨任务和难题。
金线莲是闽台特色中草药,来源于兰科(Orchidaceae)开唇兰属AnoectochilusBlume植物花叶开唇兰,全草入药,具有清热凉血、祛风利湿、解毒等功效(黄有霖.福建中药材标准.福州:海风出版社,2006:154.),多用于治疗高血压、糖尿病、肝炎和肿瘤等症,疗效甚佳,因此金线莲在民间素有“药王”、“金草”等盛誉。除花叶开唇兰外,台湾银线兰、兴仁金线兰、丽蕾金线兰等多种同属和近缘属植物,由于其与金线莲药材性状及化学成分均相似,因此在民间多用作金线莲药材(张铁,万京,沐建华.文山地区金线莲种质资源初步调查.文山师范高等专科学校学报,2005,18(1):26-28;郑纯,黄以钟,季连芳.金线莲文献考证、原植物及商品调查.中草药,1996,27(3):169-171.)。金线莲类药材主要含有内酯苷类(如金线莲苷)、多糖类和黄酮类活性成分,尤其以金线莲苷和多糖含量较高。现代药理研究表明,金线莲苷是金线莲最主要活性成分之一,具有免疫调节(Xiang M,Liu T,Tan W,Ren H,LiH,Liu J,Cao H,Cheng Q,Liu X,Zhu H,Tuo Y,Wang J,Zhang Y.Effects ofkinsenoside,a potential immunosuppressive drug for autoimmune hepatitis,ondendritic cells/CD8+T cells communication in mice.Hepatology.2016,64(6):2135-2150.)、降血糖(Zhang Y,Cai J,Ruan H,Pi H,Wu J.Antihyperglycemic activity ofkinsenoside,a high yielding constituent from Anoectochilus roxburghii instreptozotocin diabetic rats.J Ethnopharmacol.2007,114(2):141-145.)、保肝(Hsieh WT,Tsai CT,Wu JB,Hsiao HB,Yang LC,Lin WC.Kinsenoside,a high yieldingconstituent from Anoectochilus formosanus,inhibits carbon tetrachlorideinduced Kupffer cells mediated liver damage.Journal ofEthnopharmacology.2011,135(2):440-449.)、降血脂(Rehman SU,Choi MS,Kim IS,LuoZ,Xue Y,Yao G,Zhang Y,Yoo HH.In Vitro Assessment of CYP-Mediated DrugInteractions for Kinsenoside,an Antihyperlipidemic Candidate.Molecules.2016,21(6).pii:E800.)、抗炎(Hsiao HB1,Hsieh CC,Wu JB,Lin H1,Lin WC.Kinsenosideinhibits the inflammatory mediator release in a type-II collagen inducedarthritis mouse model by regulating the T cells responses.BMC ComplementAltern Med.2016,16:80)和抗骨质疏松(Hsiao HB,Lin H,Wu JB,Lin WC.Kinsenosideprevents ovariectomy-induced bone loss and suppresses osteoclastogenesis byregulating classical NF-κB pathways.Osteoporos Int.2013,24(5):1663-1676.)等生物活性,但至今未见有关金线莲及其单体化合物金线莲苷用于抗疲劳方面的报道。
发明内容
本发明的目的在于提供金线莲苷新的医药用途。
本发明的第一方面,提供金线莲苷在制备抗疲劳药物或食品中的应用。
所述的金线莲苷的化学结构如下所示:
本发明的第二方面,提供一种抗疲劳药物或食品,所述的抗疲劳药物或食品中的活性成分为金线莲苷。
优选的,所述的抗疲劳药物或食品中还包括药学上可接受的辅料。
所述的金线莲苷,其制备方法包括以下步骤:
(A)制备提取液:将开唇兰属及其近缘属植物药材粉碎后,投入提取罐,用40~90%的乙醇热提2~3次,每次溶媒用量约为生药量的8~10倍,每次提取时间为1~2小时,合并提取液;
(B)精制浓缩干燥:将步骤A得到的提取液进行浓缩,浓缩液经乙酸乙酯萃取除杂后,将水层浓缩干燥得粗提物;
(C)分离纯化:将步骤B得到的粗提物溶于水后上样大孔吸附树脂,收集0~10%乙醇洗脱部分,浓缩干燥得金线莲苷粗品,上样正向硅胶柱,采用二氯甲烷-甲醇***洗脱,收集6:1洗脱部分,得金线莲苷(纯度>90%)。
优选的,步骤A中所述的开唇兰属及其近缘属植物选自花叶开唇兰、台湾银线兰、浙江金线兰、兴仁金线兰、滇南金线兰、长片金线兰、南丹金线兰、丽蕾金线兰、高金线兰、短唇金线兰、斑叶兰、大花斑叶兰、小小斑叶兰、毛梗斑叶兰、天全斑叶兰和血叶兰中的一种或两种以上。
优选的,步骤B中所述的浓缩是减压回收溶剂。
优选的,步骤C中所述的大孔树脂选自HP-20、AB-8、D-101、ZTC-1、HPD-100或DA201中的一种。
本发明采用负重小鼠强迫游泳模型(Liu Y,Li L,An S,Zhang Y,Feng S,Zhao L,Teng L,Wang D.Antifatigue Effects of Antrodia cinnamomea Cultured Myceliumvia Modulation of Oxidative Stress Signaling in a Mouse Model.Biomed ResInt.2017:9374026.),观察本发明提供的金线莲苷灌胃给药的抗疲劳作用。此动物模型是广泛认可的抗疲劳动物模型,实验主要针对运动性疲劳,包括中枢性疲劳和外周性疲劳(王丛笑,周军.对中药抗运动性疲劳研究中动物模型的一些思考.中国实验方剂学杂志,2009,15(3):83-85;郑澜,陆爱云.运动性疲劳动物模型的研究.中国体育科技,2003,39(2):20-23;田峰.对中枢与外周运动性疲劳的再认识.中国组织工程研究,2015,19(42):6849-6854)。
实验结果显示,金线莲苷100mg/kg连续灌胃给药18天后,对小鼠正常生理情况和体重变化无显著影响;空白组小鼠负重游泳时间为1577.7±303.1秒,金线莲苷给药组小鼠负重游泳时间为2775.2±770.3秒,与空白组存在显著性差异(p<0.01);且金线莲苷还能显著降低负重游泳小鼠血清中BLD(乳酸)的含量和提高小鼠血清中LDH(乳酸脱氢酶)的活性,说明金线莲苷具有很好的抗疲劳效果。
本发明所述的抗疲劳,是指预防或治疗外周疲劳或中枢疲劳,提高机体作业能力,降低血清中乳酸的含量和提高血清中乳酸脱氢酶的活性等,改善肌肉疼痛、注意力不集中、记忆力下降等症状。
本发明寻找到了理想的抗疲劳药物。本发明提供了金线莲苷新的医药用途,经药效学研究表明,本发明的金线莲苷可显著延长负重小鼠游泳时间,抗疲劳效果显著,可用于制备抗疲劳药物或食品。本发明为寻求新的抗疲劳药物提供了一种新的来源。
附图说明
图1是动物体重随时间变化图;
图2是金线莲苷对负重小鼠游泳时间的影响(mean±SD,n=10),其中**vs空白对照组,p<0.01;
图3是金线莲苷对负重游泳小鼠血清中BLD(乳酸)水平的影响(mean±SD,n=10),其中**vs空白对照组,p<0.01;
图4是金线莲苷对负重游泳小鼠血清中LDH(乳酸脱氢酶)水平的影响(mean±SD,n=10),其中*vs空白对照组,p<0.05。
具体实施方式
下面结合实施例和附图对本发明提供的具体实施方式作详细说明。
实施例1:金线莲苷的制备
(1)制备提取液:将开唇兰属及其近缘属植物药材粉碎后,投入提取罐,用40~90%的乙醇热提2~3次,每次溶媒用量约为生药量的8~10倍,每次提取时间为1~2小时,合并提取液;
(2)精制浓缩干燥:将上述提取液进行浓缩,浓缩液经乙酸乙酯萃取除杂后,将水层浓缩干燥得粗提物;
(3)分离纯化:将上述粗提物溶于水后上样大孔吸附树脂,收集0~10%乙醇洗脱部分,浓缩干燥得金线莲苷粗品,上样正向硅胶柱,采用二氯甲烷-甲醇***洗脱,收集6:1洗脱部分,得金线莲苷(纯度>90%)。
实施例2:金线莲苷的抗疲劳药效学实验
2.1实验材料
18~22g ICR小鼠(第二军医大学实验动物中心提供)20只,小鼠LDH(乳酸脱氢酶)和BLA(血乳酸)试剂盒(南京建成生物工程研究所)。主要仪器:5L烧杯(上海禾汽玻璃仪器有限公司)、酶标仪(BIO-RAD 550)、离心机(Labofuge 400R,Heraeus公司)、电子天平(FA110A型,上海精密科学仪器有限公司)。
2.2动物分组及实验处理
实验前将20只小鼠称重,按体质量随机分为2组,每组10只,自由饮食、进水。分为空白组和金线莲苷组。空白组:给予与给药组相同体积生理盐水;金线莲苷组:灌胃给药,每日一次,剂量为100mg/kg,连续给药18d。
2.3观察指标
(1)记录各组小鼠体质量变化情况,每9天称重一次。
(2)最后一天灌胃30min后,在小鼠尾根处负重6%(铅块)让其在5L烧杯中开始游泳至7s内头不能浮出水面计时停止,计为力竭时间。
(3)取出老鼠,拨眼球取血。血液4℃、3500r/min离心10分钟,取上清保存-80℃。根据试剂盒说明书进行操作测定BLA、LDH。
2.4实验结果
采用SPSS13.0对两组数据进行两样本t检验统计学分析,P<0.05时认为差异有统计学意义。
(1)小鼠体重变化
空白组小鼠体重逐渐升高,金线莲苷给药处理后小鼠体重基本平稳,和空白组比较无显著性差异,说明金线莲苷对小鼠正常生理情况基本没影响,如图1所示。
(2)小鼠负重游泳时间
如图2所示,空白组小鼠负重力竭游泳时间为1577.7±303.1秒,金线莲苷给药组小鼠力竭负重游泳时间为2775.2±770.3秒,与空白组存在显著性差异(p<0.01),表明金线莲苷可显著增加小鼠负重游泳时间。
(3)血清指标
如图3、图4所示,金线莲苷组与空白组相比p<0.05,金线莲苷能显著降低小鼠血清中乳酸BLA的含量和提高小鼠血清中乳酸脱氢酶LDH的活性,说明金线莲苷100m g/kg灌胃给药能显著改善负重小鼠动物模型血清中的疲劳相关因子水平。
鉴于上述药效实验结果,本发明的金线莲苷具有显著抗疲劳活性,因此可用于制备抗疲劳药物或食品。
以上已对本发明创造的较佳实施例进行了具体说明,但本发明创造并不限于所述实施例,熟悉本领域的技术人员在不违背本发明创造精神的前提下还可做出种种的等同的变型或替换,这些等同的变型或替换均包含在本申请权利要求所限定的范围内。
Claims (7)
1.金线莲苷在制备抗疲劳药物或食品中的应用。
2.一种抗疲劳药物或食品,其特征在于,所述的抗疲劳药物或食品中的活性成分为金线莲苷。
3.根据权利要求2所述的抗疲劳药物或食品,其特征在于,所述的抗疲劳药物或食品中还包括药学上可接受的辅料。
4.根据权利要求2所述的抗疲劳药物或食品,其特征在于,所述的金线莲苷的制备方法包括以下步骤:
(A)制备提取液:将开唇兰属及其近缘属植物药材粉碎后,投入提取罐,用40~90%的乙醇热提2~3次,每次溶媒用量约为生药量的8~10倍,每次提取时间为1~2小时,合并提取液;
(B)精制浓缩干燥:将步骤A得到的提取液进行浓缩,浓缩液经乙酸乙酯萃取除杂后,将水层浓缩干燥得粗提物;
(C)分离纯化:将步骤B得到的粗提物溶于水后上样大孔吸附树脂,收集0~10%乙醇洗脱部分,浓缩干燥得金线莲苷粗品,上样正向硅胶柱,采用二氯甲烷-甲醇***洗脱,收集6:1洗脱部分,得金线莲苷。
5.根据权利要求4所述的抗疲劳药物或食品,其特征在于,步骤A中所述的开唇兰属及其近缘属植物选自花叶开唇兰、台湾银线兰、浙江金线兰、兴仁金线兰、滇南金线兰、长片金线兰、南丹金线兰、丽蕾金线兰、高金线兰、短唇金线兰、斑叶兰、大花斑叶兰、小小斑叶兰、毛梗斑叶兰、天全斑叶兰和血叶兰中的一种或两种以上。
6.根据权利要求4所述的抗疲劳药物或食品,其特征在于,步骤B中所述的浓缩是减压回收溶剂。
7.根据权利要求4所述的抗疲劳药物或食品,其特征在于,步骤C中所述的大孔树脂选自HP-20、AB-8、D-101、ZTC-1、HPD-100或DA201中的一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710712122.7A CN107496435B (zh) | 2017-08-18 | 2017-08-18 | 金线莲苷在制备抗疲劳药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710712122.7A CN107496435B (zh) | 2017-08-18 | 2017-08-18 | 金线莲苷在制备抗疲劳药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107496435A true CN107496435A (zh) | 2017-12-22 |
CN107496435B CN107496435B (zh) | 2021-07-27 |
Family
ID=60692317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710712122.7A Active CN107496435B (zh) | 2017-08-18 | 2017-08-18 | 金线莲苷在制备抗疲劳药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107496435B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010609A (zh) * | 2018-09-30 | 2018-12-18 | 华中科技大学 | 一种含金线莲苷的金线莲提取物的制备方法及提取物之应用 |
CN110585225A (zh) * | 2019-11-14 | 2019-12-20 | 江西厚朴贯众科技有限公司 | 金线莲苷在制备清除脑部β淀粉样蛋白斑块的药物的用途 |
CN110585227A (zh) * | 2019-11-14 | 2019-12-20 | 江西厚朴贯众科技有限公司 | 金线莲苷在制备防治神经炎症的药物中的用途 |
CN112843177A (zh) * | 2021-02-24 | 2021-05-28 | 中国人民解放军海军军医大学 | 高金线兰提取物在制备治疗或缓解疼痛的药物或保健品中的应用 |
CN113372462A (zh) * | 2021-06-03 | 2021-09-10 | 南昌大学 | 一种高纯度银线莲多糖的提取方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037462A (zh) * | 2015-08-19 | 2015-11-11 | 福建金草生物集团股份有限公司 | 一种金线莲苷的提取方法 |
CN109010609A (zh) * | 2018-09-30 | 2018-12-18 | 华中科技大学 | 一种含金线莲苷的金线莲提取物的制备方法及提取物之应用 |
-
2017
- 2017-08-18 CN CN201710712122.7A patent/CN107496435B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037462A (zh) * | 2015-08-19 | 2015-11-11 | 福建金草生物集团股份有限公司 | 一种金线莲苷的提取方法 |
CN109010609A (zh) * | 2018-09-30 | 2018-12-18 | 华中科技大学 | 一种含金线莲苷的金线莲提取物的制备方法及提取物之应用 |
Non-Patent Citations (4)
Title |
---|
HSIEH WT,TSAI CT,ET AL.: "Kinsenoside, a high yielding constituent from Anoectochilus formosanus, inhibits carbon tetrachloride induced Kupffer cells mediated liver damage.", 《J ETHNOPHAR》 * |
IKEUCHI M,YAMAGUCHI K,ET AL: "Effect of Anoectochilus formosanus on endurance capacity in mice.", 《J NUTR SCI VITAMINAL》 * |
万婷: "金线莲降血脂有效部位工艺及质量控制研究", 《武汉理工大学硕士学位论文》 * |
刘婷婷: "金线莲苷靶向树突状细胞与CD8+T细胞的相互作用抗自身免疫性肝炎作用机制研究", 《华中科技大学博士学位论文》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010609A (zh) * | 2018-09-30 | 2018-12-18 | 华中科技大学 | 一种含金线莲苷的金线莲提取物的制备方法及提取物之应用 |
CN110585225A (zh) * | 2019-11-14 | 2019-12-20 | 江西厚朴贯众科技有限公司 | 金线莲苷在制备清除脑部β淀粉样蛋白斑块的药物的用途 |
CN110585227A (zh) * | 2019-11-14 | 2019-12-20 | 江西厚朴贯众科技有限公司 | 金线莲苷在制备防治神经炎症的药物中的用途 |
CN112843177A (zh) * | 2021-02-24 | 2021-05-28 | 中国人民解放军海军军医大学 | 高金线兰提取物在制备治疗或缓解疼痛的药物或保健品中的应用 |
CN113372462A (zh) * | 2021-06-03 | 2021-09-10 | 南昌大学 | 一种高纯度银线莲多糖的提取方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107496435B (zh) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107496435A (zh) | 金线莲苷在制备抗疲劳药物中的应用 | |
CN101463061B (zh) | 三七中人参皂苷Rg1、Rb1及其总皂苷的制备方法 | |
CN102526315B (zh) | 一种荔枝核有效部位群提取物的制备方法 | |
CN103750107A (zh) | 一种具有降糖功能的保健品 | |
Ko et al. | Change of ginsenoside composition in ginseng extract by vinegar process | |
CN105294811A (zh) | 以林芝灵芝为原材料制备林芝三萜酸及灵芝多糖的方法 | |
Ghanshyam et al. | Yarsagumba: A miracle mushroom its history, cultivation, phytopharmacology and medicinal uses | |
CN107307247A (zh) | 一种牛大力植物能量功能饮料及其制备方法 | |
CN101638404B (zh) | 高纯度丹酚酸b、制备方法及应用 | |
CN103610717B (zh) | 一种采用超临界co2萃取、有机溶剂提取蜂花粉和刺五加复方提取物的制备及纯化方法 | |
CN101703561A (zh) | 一种治疗骨质疏松症的杜仲有效部位及其制备方法 | |
CN113694104B (zh) | 一种对化学性肝损伤有保护作用、促进肝脏再生的中药组合物、制备方法及其用途 | |
CN109674848A (zh) | 一种甘草提取物的制备方法与用途 | |
CN101513448B (zh) | 一种新塔花总黄酮的制备方法及其应用 | |
CN107412393B (zh) | 一种黄皮叶多酚提取物的制备方法及其应用 | |
CN110251543A (zh) | 变叶树参提取物在制备抗抑郁天然药物中的应用 | |
Hu et al. | Isolation, purification and effects of hypoglycemic functional polysaccharides from Inonotus obliquus | |
CN1302792C (zh) | 一种具有解酒保肝作用的药物组合物及其用途 | |
CN101810662B (zh) | 地胆头提取物及其制法和用途 | |
CN105456114A (zh) | 一种含有红景天提取物、何首乌提取物和灵芝提取物的美白化妆品 | |
CN1150839C (zh) | 一种具有调节血压、调节血脂作用的保健食品及其制备方法 | |
CN101214325B (zh) | 复方陈香胃药物的制备方法及其新用途 | |
CN107446705A (zh) | 一种用牛大力豆提炼精油的制备方法 | |
CN104435030B (zh) | 一种刺五加总苷的提取方法 | |
CN106913601A (zh) | 孔雀草总黄酮提取物、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |